Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Repros Therapeutics, a developer of oral small molecule drugs, has appointed Paul Lammers as its new president. Joseph Podolski remains as the company's CEO and a director.
Subscribe to our email newsletter
Prior to joining Repros, Dr Lammers was chief medical officer and member of the senior management team of EMD Serono in Rockland, Massachusetts, a division of Merck KGaA. Prior to the acquisition by Merck KGaA, Dr Lammers was the chief medical officer of Serono in Rockland, Massachusetts since 2002.
Mark Lappe, chairman of the board of Repros Therapeutics, said: “We are pleased to appoint a president with the caliber of Paul to lead Repros as it develops into a commercial biotechnology company. Paul brings a depth of experience, especially in women’s health, that will be invaluable to maximizing the worldwide potential of Proellex for the treatment of uterine fibroids and endometriosis and other disorders.”